GSK Finally Lands Human Genome With Upped $3B Offer

Law360, New York (July 16, 2012, 2:18 PM EDT) -- Human Genome Sciences Inc. finally yielded to a sweetened, $3 billion takeover offer from British drugmaker GlaxoSmithKline PLC on Monday, ending a three-month battle involving six BigLaw firms and four Wall street financial advisers.

After twice extending its offer since April, GSK finally got what it was chasing: Human Genome's gene-targeting technology, full marketing rights to the lupus drug Benlysta, and a research and development pipeline that includes promising treatments for heart disease and diabetes.

GSK will pay about $14.25 per share, up from its original...
To view the full article, register now.